高危细胞遗传学局限期侵袭性大B细胞淋巴瘤患者的结局
There is a paucity of data regarding outcomes and response to standard therapy in patients with limited-stage (LS) agressive B-cell lymphoma (LS-ABCL) who harbor MYC rearrangement (MYC-R) with or without BCL2 and/or BCL6 rearrangements.…
要点
- 更强免疫化疗较R-CHOP未改善PFS或OS。
核心结论
- 携带MYC重排的局限期侵袭性大B细胞淋巴瘤患者结局可能优于既往认识。
- 更强免疫化疗较R-CHOP未显示获益。
主要发现
- 总体缓解率91%,完全缓解率84%,部分缓解率7%。
- 中位随访3.2年,全队列2年无进展生存率78%、总生存率86%;双打击淋巴瘤患者分别为74%和81%。
- 全队列及双打击淋巴瘤患者中,IFRT与无IFRT、R-CHOP与更强免疫化疗之间PFS和OS相似。
关键数值与推荐
- 全队列2年PFS 78%、OS 86%;双打击淋巴瘤2年PFS 74%、OS 81%。
临床怎么用
- 对于MYC重排的局限期侵袭性大B细胞淋巴瘤,更强免疫化疗较R-CHOP未显示PFS或OS获益。
- IFRT与更高完全缓解率相关,但PFS和OS未显示差异。
局限性
- 回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is a paucity of data regarding outcomes and response to standard therapy in patients with limited-stage (LS) agressive B-cell lymphoma (LS-ABCL) who harbor MYC rearrangement (MYC-R) with or without BCL2 and/or BCL6 rearrangements. We conducted a multicenter retrospective study of MYC-R LS-ABCL patients who received either rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), or more intensive immunochemotherapy (IIC) plus or minus consolidative involved-field radiation therapy (IFRT). One hundred four patients from 15 academic centers were included. Forty four patients (42%) received R-CHOP, of whom 52% had IFRT. Sixty patients (58%) received IIC, of whom 40% had IFRT. Overall response rate was 91% (84% complete response [CR]; 7% partial response). Patients with double-hit lymphoma (DHL; n = 40) had a lower CR rate compared with patients with MYC-R only (75% vs 98%; P = .003). CR rate was higher in the IFRT vs no-IFRT group (98% vs 72%; P < .001). Median follow-up was 3.2 years; 2-year progression-free survival (PFS) and overal survival (OS) were 78% and 86% for the entire cohort, and 74% and 81% for the DHL patients, respectively. PFS and OS were similar across treatment groups (IFRT vs no IFRT, R-CHOP vs IIC) in the entire cohort and in DHL patients. Our data provide a historical benchmark for MYC-R LS-ABCL and LS-DHL patients and show that outcomes for this population may be better than previously recognized. There was no benefit of using IIC over R-CHOP in patients with MYC-R LS-ABCL and LS-DHL.
引用
- Torka P, Kothari SK, Sundaram S, et al. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. Blood Adv. 2020. PMID: 31945157. doi:10.1182/bloodadvances.2019000875
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。